Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Recommended Cut-Offs for the DELFIA Xpress PlGF 1-2-3 Assay

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Characteristics of Included Studies

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Biomarker Discovery, Diagnostic Assay

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Risk of Bias a,b,c Among Diagnostic Accuracy Studies (QUADAS-2 Tool)

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Diagnostic Assay, Selection

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Risk of Bias a,b,c Among Randomized Controlled Trials for the Comparison of PlGF-Based Biomarker Testing and Standard Clinical Assessment with Standard Clinical Assessment Alone

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Comparison, Biomarker Discovery, Sequencing

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Examples and Implications of Different Testing Scenarios Focusing on Accuracy

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Diagnostic Assay, Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Diagnostic GRADE Evidence Profile for the Comparison of PlGF-Based Biomarker Testing and Standard Clinical Assessment with Standard Clinical Assessment Alone

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Diagnostic Assay, Comparison, Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Prediction of Pre-eclampsia by Time Point (BRAHMS Kryptor sFlt-1/PlGF Ratio Test

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Prediction of Pre-eclampsia by Time Point (DELFIA Xpress PlGF 1-2-3 or DELFIA sFlt-1: PlGF ratio)

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Prediction of Pre-eclampsia Requiring Preterm Delivery (< 37 Weeks) (Triage PlGF Test)

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: GRADE Evidence Profile for the Comparison of PlGF-Based Biomarker Testing and Standard Clinical Assessment with Standard Clinical Assessment Alone, by Maternal Outcome

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Comparison, Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Time to Pre-eclampsia Diagnosis

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Severe Maternal Adverse Outcomes: TRIAGE PlGF Test

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Results of Economic Literature Review—Summary

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Uptake and Market Shares of PlGF-Based Biomarker Testing in the New Scenario

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Estimated Number of People Receiving PlGF-Based Biomarker Testing and Standard Clinical Assessment

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Budget Impact Analysis Results for PlGF-Based Biomarker Testing (Reference Case)

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Recommended Cut-Offs for the Elecsys Immunoassay sFlt ‑ 1/PlGF Ratio Assay

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Recommended Cut-Offs for the Triage PlGF Test

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Characteristics of Add-On (Test Results Revealed to Physician) Studies

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Characteristics of Stand-Alone (Test Results Not Revealed to Physician) Studies

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Biomarker Discovery, Control

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Prediction of Pre-eclampsia by Time Point (Elecsys sFlt-1/PlGF Ratio Test)

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Prediction of Pre-eclampsia (Triage PlGF Test)

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Prediction of Preterm Delivery (< 37 Weeks) by Test-Birth Interval (Triage PlGF Test)

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Prediction of Pre-eclampsia Requiring Delivery Within 2 Weeks (Triage PlGF Test)

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Time to Delivery: Studies Included in Systematic Review by Frampton et al

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Pre-eclampsia Diagnosis by Time Point

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Severe Pre-eclampsia

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Maternal Adverse Outcomes: Elecsys sFlt-1/PlGF Ratio Test

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Fetal Mortality Outcomes: Studies Included in the Systematic Review by Frampton et al

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Gestational Age at Delivery: Elecsys sFlt-1/PlGF Ratio Test

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Gestational Age at Delivery: Triage PlGF Test

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Perinatal Mortality: Triage PLGF Test

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Neonatal Mortality: Triage PLGF Test

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Perinatal and Neonatal Adverse Outcomes: Triage PLGF Test

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Onset of Labour: Triage PLGF Test

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Preterm and Early Preterm Delivery: Triage PLGF Test

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Maternal Admissions: Elecsys sFlt-1/PlGF Ratio Test

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Admission to Neonatal or Specialist Care Unit

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Maternal Length of Stay: Triage PlGF Test

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Nights in Neonatal Unit: Triage PlGF Test

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Costs of PlGF-Based Biomarker Testing

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Budget Impact Analysis Results for PlGF-Based Biomarker Testing (Sensitivity Analysis)

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: GRADE Evidence Profile for the Comparison of PlGF-Based Biomarker Testing and Standard Clinical Assessment with Standard Clinical Assessment Alone, by Fetal and Neonatal Outcome

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Comparison, Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: GRADE Evidence Profile for the Comparison of PlGF-Based Biomarker Testing and Standard Clinical Assessment with Standard Clinical Assessment Alone, by Hospitalization and Quality of Life Outcome

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Comparison, Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet:

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Diagnostic Assay

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Assessment of the Applicability of Studies Evaluating the Cost-Effectiveness of PlGF-Based Biomarker Testing

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: Biomarker Discovery

Journal: Ontario Health Technology Assessment Series

Article Title: Placental Growth Factor (PlGF)– Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment

doi:

Figure Lengend Snippet: Studies Not Applicable to the Ontario Setting

Article Snippet: Regulatory Information Seven PlGF-based biomarker tests on the market, four of which are licensed by Health Canada.13. . DELFIA Xpress PlGF 1-2-3 (Wallac Oy, Turku, Finland) The DELFIA Xpress PLGF 1‐2‐3 test (licence no. 65353) The test is intended to help predict the risk of pre-eclampsia in the short term and/or diagnose suspected pre-eclampsia in conjunction with other clinical information.

Techniques: